Free Republic

July 10 (Reuters) - The U.S. Food and Drug Administration has granted full approval for Moderna's (MRNA.O), opens new tab COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease, the company said on Thursday. The shot was previously available for pediatric populations under emergency use authorization. Moderna expects to make its updated vaccine available for eligible U.S. population for the 2025-26 respiratory virus season. Health secretary Robert F. Kennedy Jr. had in May said the U.S. has stopped recommending routine COVID-19 vaccinations for healthy children and healthy pregnant women....